

Caroline Gordon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2991074/publications.pdf>

Version: 2024-02-01

223
papers

21,877
citations

14655
66
h-index

9589
142
g-index

229
all docs

229
docs citations

229
times ranked

14534
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. Arthritis Care and Research, 2022, 74, 1623-1630.	3.4	3
2	Medication decision-making and adherence in lupus: patientâ€“physician discordance and the impact of previous â€“adverse medical experiencesâ€™. Rheumatology, 2022, 61, 1417-1429.	1.9	7
3	Telemedicine in rheumatology: a mixed methods study exploring acceptability, preferences and experiences among patients and clinicians. Rheumatology, 2022, 61, 2262-2274.	1.9	45
4	Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology, 2022, 61, 4006-4015.	1.9	14
5	Will â€“the feeling of abandonmentâ€™ remain? Persisting impacts of the COVID-19 pandemic on rheumatology patients and clinicians. Rheumatology, 2022, 61, 3723-3736.	1.9	6
6	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
7	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
8	The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus. Rheumatology, 2022, 61, 3329-3340.	1.9	2
9	Chilblains in immune-mediated inflammatory diseases: a review. Rheumatology, 2022, 61, 4631-4642.	1.9	8
10	FC055: Effect of Atacicept on Renal Function in SLE Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
11	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. Lupus Science and Medicine, 2022, 9, e000584.	2.7	5
12	Access and Costâ€“Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program. Arthritis Care and Research, 2021, 73, 1561-1567.	3.4	16
13	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	3.4	13
14	Flares in patients with systemic lupus erythematosus. Rheumatology, 2021, 60, 3262-3267.	1.9	5
15	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	3.4	22
16	Constitutional symptoms and fatigue in systemic lupus erythematosus. , 2021, , 351-359.		0
17	Malignancies in systemic lupus erythematosus. , 2021, , 461-467.		0
18	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Annals of the Rheumatic Diseases, 2021, 80, 1.1-2.	0.9	31

#	ARTICLE	IF	CITATIONS
19	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. Rheumatology, 2021, 60, 1480-1490.	1.9	7
20	“But you don’t look sick”: a qualitative analysis of the LUPUS UK online forum. Rheumatology International, 2021, 41, 721-732.	3.0	12
21	Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLE—data from the BSR audit of systemic lupus erythematosus. Rheumatology, 2021, 60, 1474-1479.	1.9	8
22	Malignancy risk and screening. , 2021, , 583-598.		0
23	COVID-19 and shielding: experiences of UK patients with lupus and related diseases. Rheumatology Advances in Practice, 2021, 5, rab003.	0.7	18
24	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology, 2021, 60, 4737-4747.	1.9	14
25	Prescribing anti-rheumatic drugs in pregnancy and breastfeeding—the British Society for Rheumatology guideline scope. Rheumatology, 2021, 60, 3565-3569.	1.9	5
26	Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis and Rheumatology, 2021, 73, 991-996.	5.6	114
27	O19—Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004. Rheumatology, 2021, 60, .	1.9	0
28	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	1.6	3
29	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
30	Understanding the impact of systemic lupus erythematosus on work amongst South Asian people in the UK: An explorative qualitative study. Lupus, 2021, 30, 1492-1501.	1.6	3
31	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. Arthritis Research and Therapy, 2021, 23, 203.	3.5	3
32	The impact of the COVID-19 pandemic on the medical care and health-care behaviour of patients with lupus and other systemic autoimmune diseases: a mixed methods longitudinal study. Rheumatology Advances in Practice, 2021, 5, ra0072.	0.7	22
33	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. Annals of Internal Medicine, 2021, 174, 1647-1657.	3.9	64
34	1124—Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
35	1107—Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
36	1704—Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
37	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
38	Epidemiology of disease-activity related ophthalmological manifestations in Systemic Lupus Erythematosus: A systematic review. <i>Lupus</i> , 2021, 30, 2191-2203.	1.6	5
39	Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. <i>Lupus Science and Medicine</i> , 2021, 8, e000614.	2.7	17
40	Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , 2020, 72, 874-881.	3.4	31
41	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 72-81.	2.0	34
42	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
43	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	3.4	23
44	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
45	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
46	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
47	Medications in pregnancy and breastfeeding. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 64, 68-76.	2.8	14
48	Is it me? The impact of patient-physician interactions on lupus patients' psychological well-being, cognition and health-care-seeking behaviour. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa037.	0.7	28
49	Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan. <i>Trials</i> , 2020, 21, 652.	1.6	4
50	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9
51	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
52	Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa006.	0.7	31
53	Cancer and Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 533-550.	1.9	22
54	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. <i>Arthritis Care and Research</i> , 2019, 71, 949-960.	3.4	38

#	ARTICLE	IF	CITATIONS
55	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70
56	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Science and Medicine, 2019, 6, e000344.	2.7	22
57	233â€“Enhancing quality improvement capacity through the British Society for Rheumatologyâ€™s multi-region audit into the management of adults with systemic lupus erythematosus. Rheumatology, 2019, 58, .	1.9	0
58	Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatology Advances in Practice, 2019, 3, rkz021.	0.7	8
59	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	2.0	15
60	Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nature Reviews Rheumatology, 2019, 15, 391-402.	8.0	33
61	1061â€“Cancer and lupus: what are the links and what should we be looking out for?. Rheumatology, 2019, 58, .	1.9	0
62	1082â€“To stop or not to stop? The effect of anti-rheumatic drugs in pregnancy. Rheumatology, 2019, 58, .	1.9	0
63	1095â€“Management of lupus in pregnancy. Rheumatology, 2019, 58, .	1.9	0
64	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 736-745.	0.9	1,265
65	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
66	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
67	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open, 2019, 9, e032569.	1.9	35
68	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
69	Current challenges in the development of new treatments for lupus. Annals of the Rheumatic Diseases, 2019, 78, 729-735.	0.9	39
70	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
71	Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. Arthritis Care and Research, 2019, 71, 95-103.	3.4	38
72	Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus â€“ Fulton and DeKalb Counties, Georgia, 2002â€“2016. Morbidity and Mortality Weekly Report, 2019, 68, 419-422.	15.1	59

#	ARTICLE	IF	CITATIONS
73	Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus – Michigan Lupus Epidemiology and Surveillance Program, 2014–2015. Morbidity and Mortality Weekly Report, 2019, 68, 819-824.	15.1	18
74	Obituary for Paul Bacon. Rheumatology, 2018, 57, 943-945.	1.9	0
75	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 763-773.	5.6	49
76	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 393-396.	2.0	27
77	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
78	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
79	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology, 2018, 57, 14-18.	1.9	43
80	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 2018, 57, 470-479.	1.9	73
81	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology, 2018, 57, e1-e45.	1.9	247
82	Epratuzumab for the treatment of systemic lupus erythematosus. Expert Review of Clinical Immunology, 2018, 14, 245-258.	3.0	31
83	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
84	CS-07...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
85	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. Rheumatology, 2018, 57, 1502-1503.	1.9	12
86	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
87	Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue?. Journal of Rheumatology, 2017, 44, 398.1-398.	2.0	68
88	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis and Rheumatology, 2017, 69, 2006-2017.	5.6	126
89	The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. Arthritis and Rheumatology, 2017, 69, 1996-2005.	5.6	135
90	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. Rheumatology, 2017, 56, 1041-1043.	1.9	2

#	ARTICLE	IF	CITATIONS
91	Prevalence of Mixed Connective Tissue Disease in a Population-Based Registry of American Indian/Alaska Native People in 2007. <i>Arthritis Care and Research</i> , 2017, 69, 1271-1275.	3.4	10
92	Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BlyS and APRIL. <i>Arthritis and Rheumatology</i> , 2017, 69, 122-130.	5.6	37
93	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	5.6	189
94	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	3.5	1
95	Malignancies in Systemic Lupus Erythematosus. , 2016, , 411-415.		0
96	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	5.6	40
97	Constitutional Symptoms and Fatigue in Systemic Lupus Erythematosus. , 2016, , 317-324.		2
98	Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry. <i>Arthritis Care and Research</i> , 2016, 68, 357-365.	3.4	31
99	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016, 68, 1505-1513.	3.4	45
100	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16039.	30.5	816
101	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeedingâ€”Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1. <i>Rheumatology</i> , 2016, 55, 1693-1697.	1.9	350
102	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeedingâ€”Part II: analgesics and other drugs used in rheumatology practice: Table 1. <i>Rheumatology</i> , 2016, 55, 1698-1702.	1.9	129
103	From BILAG to BILAG-based combined lupus assessmentâ€”30 years on. <i>Rheumatology</i> , 2016, 55, 1357-1363.	1.9	21
104	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
105	Hydroxychloroquine-related retinal toxicity. <i>Rheumatology</i> , 2016, 55, 957-967.	1.9	77
106	Systemic lupus erythematosus: An update for ophthalmologists. <i>Survey of Ophthalmology</i> , 2016, 61, 65-82.	4.0	29
107	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 904-913.	0.7	97
108	Fertility and pregnancy in autoimmune rheumatic diseases. <i>Indian Journal of Rheumatology</i> , 2016, 11, 115.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Incidence and Prevalence of Systemic Lupus Erythematosus Among Arab and Chaldean Americans in Southeastern Michigan: The Michigan Lupus Epidemiology and Surveillance Program. <i>American Journal of Public Health</i> , 2015, 105, e74-e79.	2.7	29
110	The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2015, 34, 263-271.	2.2	17
111	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	5.6	98
112	Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 128-135.	3.4	39
113	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2006-2015.	0.9	231
114	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.9	70
115	Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. <i>Rheumatology</i> , 2015, 54, 836-843.	1.9	92
116	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
117	Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. <i>Immunotherapy</i> , 2014, 6, 1165-1175.	2.0	8
118	The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002–2004: The Georgia Lupus Registry. <i>Arthritis and Rheumatology</i> , 2014, 66, 357-368.	5.6	269
119	Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. <i>BMJ Open</i> , 2014, 4, e004081.	1.9	66
120	Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies. <i>Lupus Science and Medicine</i> , 2014, 1, e000034.	2.7	16
121	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 183-190.	0.9	266
122	Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. <i>Rheumatology</i> , 2014, 53, 502-511.	1.9	64
123	Advances in the assessment of lupus disease activity and damage. <i>Current Opinion in Rheumatology</i> , 2014, 26, 510-519.	4.3	28
124	Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis and Rheumatology</i> , 2014, 66, 369-378.	5.6	343
125	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138-142.	0.9	115
126	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558

#	ARTICLE	IF	CITATIONS
127	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , 2014, 53, 275-284.	1.9	71
128	Interferon- γ -induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erythematosus monocytes. <i>Rheumatology</i> , 2014, 53, 2249-2258.	1.9	47
129	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 875-880.	2.0	28
130	25-Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1167-1176.	3.4	49
131	Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People, 2007-2009. <i>Arthritis and Rheumatology</i> , 2014, 66, 2494-2502.	5.6	103
132	Systemic Lupus Erythematosus and Malignancies. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 497-506.	1.9	25
133	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	6.5	249
134	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
135	<i>Rheumatic Disease</i> . , 2013, , 1415-1440.		0
136	B-Cell Targeted Therapies in Systemic Lupus Erythematosus. <i>BioDrugs</i> , 2013, 27, 85-95.	4.6	37
137	New biologic therapy for systemic lupus erythematosus. <i>Current Opinion in Pharmacology</i> , 2013, 13, 405-412.	3.5	24
138	Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e002852.	1.9	19
139	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1308-1314.	0.9	78
140	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , 2013, 52, 1313-1322.	1.9	115
141	Mortality in SLE. , 2013, , 666-675.		3
142	In Utero Azathioprine Exposure and Increased Utilization of Special Educational Services in Children Born to Mothers With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2013, 65, 759-766.	3.4	44
143	Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al. <i>Arthritis Care and Research</i> , 2013, 65, 1391-1392.	3.4	0
144	The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. <i>Rheumatology</i> , 2013, 52, 2292-2301.	1.9	72

#	ARTICLE	IF	CITATIONS
145	Malignancies in systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2013, 8, 275-280.	0.3	0
146	Systemic lupus and malignancies. Current Opinion in Rheumatology, 2012, 24, 177-181.	4.3	36
147	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
148	The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. Rheumatology, 2012, 51, 1877-1880.	1.9	28
149	The BILAG-2004 systems tallyâ€”a novel way of representing the BILAG-2004 index scores longitudinally. Rheumatology, 2012, 51, 2099-2105.	1.9	13
150	Joint European League Against Rheumatism and European Renal Associationâ€”European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, 2012, 71, 1771-1782.	0.9	868
151	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
152	Refractory multisystem sarcoidosis responding to infliximab therapy. Clinical Rheumatology, 2012, 31, 1013-1018.	2.2	16
153	Co-morbidities in Systemic Lupus Erythematosus. , 2012, , 229-249.		0
154	Managing pregnancy in inflammatory rheumatological diseases. Arthritis Research and Therapy, 2011, 13, 206.	3.5	49
155	Causes and management of infertility in systemic lupus erythematosus. Rheumatology, 2011, 50, 1551-1558.	1.9	69
156	Decreased live births in women with systemic lupus erythematosus. Arthritis Care and Research, 2011, 63, 1068-1072.	3.4	34
157	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology, 2011, 50, 982-988.	1.9	155
158	Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology, 2011, 50, 657-664.	1.9	112
159	Systemic lupus erythematosus: Clinical presentations. Autoimmunity Reviews, 2010, 10, 43-45.	5.8	108
160	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, openâ€”label, parallelâ€”group clinical trial. Arthritis and Rheumatism, 2010, 62, 211-221.	6.7	139
161	Efficacy and safety of rituximab in moderatelyâ€”toâ€”severely active systemic lupus erythematosus: The randomized, doubleâ€”blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis and Rheumatism, 2010, 62, 222-233.	6.7	1,111
162	Numerical scoring for the BILAG-2004 index. Rheumatology, 2010, 49, 1665-1669.	1.9	111

#	ARTICLE	IF	CITATIONS
163	The LupusQoL and Associations with Demographics and Clinical Measurements in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 2273-2279.	2.0	54
164	Contemporary treatment of systemic lupus erythematosus: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 163-175.	2.5	52
165	The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. <i>Rheumatology</i> , 2010, 49, 723-732.	1.9	79
166	Clinical trials in lupus: what have we learned so far?. <i>Rheumatology</i> , 2010, 49, 1025-1027.	1.9	17
167	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. <i>Journal of Rheumatology</i> , 2010, 37, 322-329.	2.0	83
168	Novel treatments for systemic lupus erythematosus. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1256-64.	2.3	14
169	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , 2009, 48, 1548-1552.	1.9	35
170	Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. <i>Rheumatology</i> , 2009, 48, 1506-1511.	1.9	107
171	Adverse events and efficacy of TNF- α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. <i>Rheumatology</i> , 2009, 48, 1451-1454.	1.9	173
172	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009, 48, 691-695.	1.9	90
173	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 470-476.	0.9	36
174	Assessment of disease activity and quality of life in systemic lupus erythematosus – New aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 457-467.	3.3	35
175	Challenges of ethnicity in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 549-561.	3.3	27
176	Experience with a Punjabi, Urdu and Hindi rheumatology telephone helpline. <i>Musculoskeletal Care</i> , 2009, 7, 210-218.	1.4	9
177	Biologic therapy and pregnancy outcomes in women with rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2009, 61, 587-592.	6.7	68
178	Population-based lupus registries: Advancing our epidemiologic understanding. <i>Arthritis and Rheumatism</i> , 2009, 61, 1462-1466.	6.7	61
179	Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis. <i>Expert Review of Clinical Immunology</i> , 2009, 5, 27-34.	3.0	7
180	Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , 2008, 58, 1784-1788.	6.7	66

#	ARTICLE	IF	CITATIONS
181	Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response. Arthritis and Rheumatism, 2008, 58, 1789-1795.	6.7	15
182	Systemic lupus erythematosus in women: Impact on family size. Arthritis and Rheumatism, 2008, 59, 1656-1660.	6.7	25
183	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2007, 66, 569-570.	0.9	2
184	Pregnancy and rheumatic diseases. Rheumatology, 2007, 46, 1634-1640.	1.9	72
185	Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. Rheumatology, 2007, 47, 334-338.	1.9	43
186	Ocular manifestations of systemic lupus erythematosus. Rheumatology, 2007, 46, 1757-1762.	1.9	184
187	The systemic lupus erythematosus Tri-Nation study: Cumulative indirect costs. Arthritis and Rheumatism, 2007, 57, 64-70.	6.7	58
188	Tumor necrosis factor α activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis and Rheumatism, 2007, 56, 1776-1786.	6.7	63
189	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 57, 972-979.	6.7	252
190	British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 4113-4119.	6.7	96
191	Constitutional Features of Systemic Lupus Erythematosus. , 2007, , 329-335.		0
192	Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R120.	3.5	80
193	Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Research and Therapy, 2006, 8, 209.	3.5	469
194	Large vessel vasculitides. Medicine, 2006, 34, 468-471.	0.4	3
195	Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: Comment on the article by Ruperto et al. Arthritis and Rheumatism, 2006, 54, 2343-2344.	6.7	1
196	Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity. Arthritis and Rheumatism, 2006, 54, 3300-3305.	6.7	93
197	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis and Rheumatism, 2006, 55, 892-899.	6.7	95
198	Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Practice and Research in Clinical Rheumatology, 2005, 19, 685-708.	3.3	281

#	ARTICLE	IF	CITATIONS
199	Mycophenolate Mofetil for Remission Induction in Severe Lupus Nephritis. <i>Nephron Clinical Practice</i> , 2005, 100, c92-c100.	2.3	32
200	Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. <i>Arthritis Research and Therapy</i> , 2005, 7, R784-95.	3.5	425
201	Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 231-8.	2.0	108
202	Pregnancy and autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 359-379.	3.3	57
203	Pregnancy and autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 359-379.	3.3	17
204	Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. <i>Journal of Rheumatology</i> , 2004, 31, 2390-4.	2.0	37
205	Lupus and zoster. <i>Lancet, The</i> , 2003, 362, 616.	13.7	5
206	Primary Anti-Phospholipid Antibody Syndrome (APS). <i>Survey of Ophthalmology</i> , 2002, 47, 215-238.	4.0	78
207	A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves' disease: Comment on the article by Rood et al. <i>Arthritis and Rheumatism</i> , 2002, 46, 3109-3110.	6.7	24
208	Update on systemic lupus erythematosus: autoantibodies and apoptosis. <i>Clinical Medicine</i> , 2001, 1, 10-14.	1.9	31
209	The use of alternative medical therapies in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000, 43, 1410-1418.	6.7	60
210	Quality of life and economic evaluation in SLE clinical trials. <i>Lupus</i> , 1999, 8, 645-654.	1.6	37
211	Factors Involved in the Pathogenesis of Neutrophilic Vasculitis in MRL/Mp-lpr/lpr Mice: A Model for Human Microscopic Angiitis. <i>Autoimmunity</i> , 1999, 31, 133-145.	2.6	5
212	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 1997, 40, 809-813.	6.7	586
213	The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. <i>Arthritis and Rheumatism</i> , 1995, 38, 551-558.	6.7	328
214	A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. <i>European Journal of Immunology</i> , 1994, 24, 191-195.	2.9	212
215	Clinical Pharmacology and Modification of Autoimmunity and Inflammation in Rheumatoid Disease. <i>Drugs</i> , 1994, 47, 259-285.	10.9	7
216	Chronic therapy with recombinant tumor necrosis factor- α in autoimmune NZB/NZW F1 mice. <i>Clinical Immunology and Immunopathology</i> , 1989, 52, 421-434.	2.0	159

#	ARTICLE	IF	CITATIONS
217	Rheumatoid Arthritis/SLE. , 0, , 267-281.		0
218	E89.â€ŒThe Disease-Specific Lupusqol is Sensitive to Change In Patients with Moderate or Severe Systemic Lupus Erythematosus after Treatment of a Flare. Rheumatology, 0, , .	1.9	0
219	Drugs in Rheumatic Disease During Pregnancy. , 0, , 98-113.		1
220	Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. Arthritis Care and Research, 0, , .	3.4	2
221	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0
222	Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology, 0, , .	1.9	2
223	Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 0, , .	3.3	0